pas-5 Antibody
Description
Overview of PAX-5 Antibody
PAX-5 (Paired Box 5) antibody is a B-cell-specific transcription factor critical for B-lymphocyte development and differentiation. It targets the PAX-5 protein, also known as B-cell-specific activator protein (BSAP), which regulates genes like CD19 and CD20 during early B-cell maturation . PAX-5 is expressed in pro-B, pre-B, and mature B-cells but absent in plasma cells, making it a highly specific pan-B-cell marker for diagnostic pathology .
Key Roles in Pathology
-
B-Cell Malignancies: PAX-5 is consistently expressed in precursor and mature B-cell non-Hodgkin lymphomas (e.g., diffuse large B-cell lymphoma) and classic Hodgkin lymphoma (97% of cases) .
-
Differential Diagnosis:
Comparative Performance
Study Cohort Analysis (n=592)
PAX-5 immunostaining demonstrated:
-
100% sensitivity in precursor B-cell acute lymphoblastic leukemia .
-
96% specificity for B-cell lineage, with no cross-reactivity in T-cell malignancies .
-
Utility in distinguishing lymphoplasmacytic lymphoma (PAX-5+) from plasmacytoma (PAX-5-) .
Mechanistic Insights
PAX-5 suppresses non-B-cell genes during lineage commitment and maintains B-cell identity via transcriptional regulation . Loss of PAX-5 correlates with plasma cell differentiation, mediated by Blimp-1 upregulation .
Limitations and Innovations
Product Specs
Target Background
Q&A
Based on analysis of current research and clinical studies, here is a structured FAQ addressing key scientific considerations for PAS-5 antibody research:
Advanced Research Challenges
How to resolve contradictory findings in PAS-5 antibody cross-reactivity studies?
A three-step validation framework addresses discordant results:
-
Epitope mapping: Use HDX-MS to confirm binding specificity
-
Technical validation: Parallel testing with ELISA/CLIA/Western blot
What computational models predict PAS-5 antibody developability?
Recent advances integrate:
| Parameter | Optimal Range | High-Risk Profile |
|---|---|---|
| Hydrophobicity | 0.2-0.4 | >0.6 |
| pI | 6.8-8.2 | <6.0 |
| Stability index | ≥1.5 | <1.0 |
Molecular dynamics simulations should exceed 500ns to assess aggregation propensity .
Methodological Considerations Table
| Research Phase | Key Metrics | Validation Approach | Common Pitfalls |
|---|---|---|---|
| Target Engagement | SPR KD ≤1nM | BLI cross-validation | Non-specific binding in serum matrix |
| Preclinical Safety | hERG IC50 >30μM | CiPA-compliant assays | Off-target cytokine release |
| Clinical Correlation | AUC ≥0.85 | ROC curve analysis | Population stratification bias |
Emerging Research Frontiers
What multi-omics approaches strengthen PAS-5 antibody mechanism studies?
Integrated analysis frameworks:
-
Transcriptomic: Single-cell RNA-seq of CD19+ B-cell clusters
-
Proteomic: Olink PEA for 92 inflammation markers
-
Metabolomic: LC-MS/MS salivary gland profiling
Pilot data shows IL-4/IL-13 pathway activation (FDR=0.003) in high PAS-5 cohorts .
